Global

The region is moving to the forefront in integrating therapeutic innovation.

Is it possible to win in Asia’s private market?

The three key themes likely to shape pharma fortunes in 2024.

A growing number of domestic drug developers are setting their sights on overseas markets.

An overview of what biopharma C-Suites and their boards should consider when engaging with government and business leaders from China, the world’s second largest economy.

Raja discusses how the pharma industry can improve its ecological impact.

Effective engagement—from research to reimbursement—is key.

The treatment is approved for conditional marketing authorization.

Attempts to capitalize on the region’s vibrant R&D scene are heating up.

Some new EU plans "fly in the face" of innovation, critics contend.

Advancing the concept of "health competencies" remains elusive.

More opinions enter the mix as EU launches legislation review.

The UK BioIndustry Association and Clarivate detail current economic trends in the UK Biotech Financing Report.

The time is ripe to double down on local “market-fit” capabilities.

US pharma industry handcuffed by restrictions, group argues.

Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.

An ecosystem perspective is the first step.

Member states air concerns over excess supplies of COVID vaccines.

Making sense of surprise rejection of draft proposals.

Commercial Health Insurance may bring more opportunities for market access in China.

Global go-to-market strategies in region require a revamped gameplan.

Patient safety and data protection concerns highlight hesitancy.

The 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.

The rare disease market in China can be summed up in three words: Exciting, challenging, and fast evolving. As such it’s quite a complicated space that requires a careful and strategic approach. In this article experts from Simon-Kucher discuss how best to navigate this landscape to reap the many opportunities available.

And, in equal measure, patients and doctors—as EU mulls new rules.

Proposed SoHO reform elicits wide support, but risks acknowledged.

Jimenez discusses bringing care to diverse and underserved communities.

Industry leaders discuss new technologies, research, and investment strategies.

Continent has shed its ‘emerging’ status on world biopharma stage.